Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias
NCT03135769Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Feb 2017
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab in gestational trophoblastic neoplasia (GTN), sponsored by Hospices Civils de Lyon. Primary endpoint: Rate of patients with successful normalization of hCG assays at 6 months. Started Feb 2017; status: completed.
02
Drugs
avelumab
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT03135769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135769.